About

Nam Quoc Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute, specializing in Sarcoma. He earned his undergraduate degree in Computer Science from Stanford University and his medical degree from the University of Texas Southwestern Medical Center. Dr. Bui completed his Internal Medicine residency at Stanford Hospital and a Hematology/Oncology fellowship at the University of California San Diego, where he conducted extensive research in bioinformatics to analyze tumor sequencing data. His research interests include the application of bioinformatics to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to translate new therapeutics from the lab to clinical practice. Dr. Bui serves as a lecturer and mentor to medical students, residents, and oncology fellows at Stanford University School of Medicine. He is the founding Editor-in-Chief of the journal 'Current Problems in Cancer: Case Reports' and serves as the Chair of the Data Safety Monitoring Committee at the Stanford Cancer Institute, overseeing all investigator-initiated cancer trials at Stanford.

Research topics

• Computer Science
• Medicine
• Data Mining
• Internal medicine
• Biology
• Genetics
• Computational biology
• Molecular biology
• Pathology
• Botany
• Oncology
• Surgery
• Gastroenterology

Selected publications

• Supplementary Figure S11 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-06

  articleOpen access

  <p>Supplementary Figure S11 shows that p53 drives LUAD regression through macrophage activation.</p>

  PublisherDOI

• Supplementary Table 5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>List of genes upregulated with restoration of p5325,26,53,54, relative to p53null cells.</p>

  PublisherDOI

• Supplementary Table 1 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Gene lists of the RNA-seq analyses of p53null, p53wt-restored, p5353,54-restored, p5325,26-restored, and p5325,26,53,54-restored LUAD cells.</p>

  PublisherDOI

• Supplementary Figure S9 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S9 shows that knockdown of TSC2 dampens the p53 pathway.</p>

  PublisherDOI

• Supplementary Table 6 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>List of differentially expressed genes with restoration of p53wt that overlap with p53-bound genes.</p>

  PublisherDOI

• Supplementary Figure S2 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S2 shows that restoration of p53wt or p5353,54 induces LUAD regression and mild apoptosis in vivo.</p>

  PublisherDOI

• Supplementary Figure S7 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S7 analysize the autophagy and lysosomal genes that are regulated by TFEB.</p>

  PublisherDOI

• Supplementary Figure S3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S3 shows that restoration of p5353,54 in LUAD induces cell differentiation.</p>

  PublisherDOI

• Supplementary Figure S10 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S10 shows that treatment of wild-type p53-expressing cells with an MDM2 antagonist across contexts.</p>

  PublisherDOI

• Supplementary Figure S5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program

  2026-02-09

  articleOpen access

  <p>Supplementary Figure S5 assesses transcriptional activities of p53 TAD mutants using RNA-seq.</p>

  PublisherDOI

Frequent coauthors

• Kristen N. Ganjoo

  Stanford University

  220 shared

• Stefano Testa

  Beth Israel Deaconess Medical Center

  108 shared

• Gregory W. Charville

  Stanford University

  41 shared

• Matt van de Rijn

  41 shared

• Maggie Zhou

  33 shared

• Minggui Pan

  32 shared

• Everett J. Moding

  Stanford University

  31 shared

• Ajay Subramanian

  29 shared

Labs

• Stanford Cancer InstitutePI